# A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other

Source: https://onco.cc/trials/nct05081609/  
OnCo record `nct05081609` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Pembrolizumab, Trastuzumab, Trastuzumab emtansine in ovarian cancer and melanoma, run by Ascendis Pharma Oncology Division A/S, active and no longer recruiting.

## Summary

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies is a phase 1/2 interventional study registered as NCT05081609 by Ascendis Pharma Oncology Division A/S, with 320 participants enrolled, started 2022-01-11 and due to reach its primary completion in 2027-08. Interventions recorded: TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery. Conditions listed: Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05081609
- Phase: 1/2
- Setting: IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, TransCon TLR7/8 Agonist, or Other Anticancer Therapies, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
- Sponsor: Ascendis Pharma Oncology Division A/S
- Enrolled: 320

## Sources

- ClinicalTrials.gov NCT05081609: https://clinicaltrials.gov/study/NCT05081609

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab emtansine](https://onco.cc/drugs/trastuzumab-emtansine/)

---
JSON: https://onco.cc/api/v1/entities/nct05081609.json